Cancer Registry Software - Global ﾂ鮓ｹﾔｭｴｴ Outlook (2017-2026)

Publication ID:

SMRC0319028

Publication Date:

March 1, 2019

Pages:

157

Publisher:

Stratistics MRC

Countries:

Global [1]

USD 4,150.00

Healthcare [2]

Pharma & Healthcare [3]

Software [4]

Computing & Electronics [5]

Description:

The Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ is accounted for $43.2 million in 2017 and is expected to reach $112.2 million by 2026 growing at a CAGR of 11.2% from 2017 to 2026. Some of the factors such as increase in prevalence of cancer and favorable government initiatives are impelling the market growth. However privacy and data security-related concerns are restricting the market growth. Increase in number of accountable care organizations is creating ample opportunities for the market growth.

Cancer Registry Software is a particular type of disease registry that is mainly used in order to establish and maintain a cancer incidence reporting system. The cancer registry system acts as an informational resource for the investigation of cancer and its causes. This type of registry is important as cancer is among the leading causes of death and therefore the collection of data on cancer cases from diagnosis through survivorship is beneficial in order to help identify trends and ultimately improve care for patients that are fighting cancer.

Based on type, the standalone software segment accounted for a larger share primarily due to the significant use of standalone software by government organizations & TPAs for population health management (due to its adaptability and interoperability). Also, standalone software provides practical and easy-to-use tools to store and process registry data, while standalone software customized for patient registries offers higher flexibility and features such as multiple system usage and automatic upgradation. Based on the geography, North America dominated the market growth due to the high burden of cancer, government funding initiatives to encourage the development of cancer registries.

Some of the key players in Cancer Registry Software market include, Onco, Inc., Rocky Mountain Cancer Data Systems, Mckesson Corporation, Elekta AB (PUB), C/Net Solutions and Electronic Registry Systems, Inc.

Types Covered:
窶｢ Integrated Software
窶｢ Standalone Software

Deployment Models Covered:
窶｢ Cloud-Based Models
窶｢ On-Premise Models

Database Types Covered:
窶｢ Commercial Databases
窶｢ Public Databases

Functionalities Covered:
窶｢ Patient Care Management
窶｢ Product Outcome Evaluation
窶｢ Cancer Reporting to Meet State and Federal Regulations
窶｢ Medical Research & Clinical Studies

End Users Covered:
窶｢ Hospitals & Medical Practices
窶｢ Government Organizations & Third-Party Administrators
窶｢ Pharmaceutical, Biotechnology, and Medical Device Companies
窶｢ Private Payers
窶｢ Research Centers
窶｢ Other End Users

Regions Covered:
窶｢ North America
o US
o Canada
o Mexico
窶｢ Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
窶｢ Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
窶｢ South America
o Argentina
o Brazil
o Chile
o Rest of South America
窶｢ Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- ﾂ鮓ｹﾔｭｴｴ share assessments for the regional and country level segments
- ﾂ鮓ｹﾔｭｴｴ share analysis of the top industry players
- Strategic recommendations for the new entrants
- ﾂ鮓ｹﾔｭｴｴ forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- ﾂ鮓ｹﾔｭｴｴ Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
窶｢ Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
窶｢ Regional Segmentation
o ﾂ鮓ｹﾔｭｴｴ estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
窶｢ Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table Of Contents:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 ﾂ鮓ｹﾔｭｴｴ Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging ﾂ鮓ｹﾔｭｴｴs
3.8 Futuristic ﾂ鮓ｹﾔｭｴｴ Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ, By Type
5.1 Introduction
5.2 Integrated Software
5.3 Standalone Software

6 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ, By Deployment Model
6.1 Introduction
6.2 Cloud-Based Models
6.3 On-Premise Models

7 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ, By Database Type
7.1 Introduction
7.2 Commercial Databases
7.3 Public Databases

8 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ, By Functionality
8.1 Introduction
8.2 Patient Care Management
8.3 Product Outcome Evaluation
8.4 Cancer Reporting to Meet State and Federal Regulations
8.5 Medical Research & Clinical Studies

9 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ, By End User
9.1 Introduction
9.2 Hospitals & Medical Practices
9.3 Government Organizations & Third-Party Administrators
9.4 Pharmaceutical, Biotechnology, and Medical Device Companies
9.5 Private Payers
9.6 Research Centers
9.7 Other End Users

10 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa

11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling
12.1 Onco, Inc.
12.2 Rocky Mountain Cancer Data Systems
12.3 Mckesson Corporation
12.4 Elekta AB (PUB)
12.5 C/Net Solutions
12.6 Electronic Registry Systems, Inc.

List of Tables
1 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Region (2016-2026) (US $MN)
2 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Type (2016-2026) (US $MN)
3 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Integrated Software (2016-2026) (US $MN)
4 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Standalone Software (2016-2026) (US $MN)
5 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Deployment Model (2016-2026) (US $MN)
6 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cloud-Based Models (2016-2026) (US $MN)
7 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By On-Premise Models (2016-2026) (US $MN)
8 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Database Type (2016-2026) (US $MN)
9 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Commercial Databases (2016-2026) (US $MN)
10 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Public Databases (2016-2026) (US $MN)
11 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Functionality (2016-2026) (US $MN)
12 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Patient Care Management (2016-2026) (US $MN)
13 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Outcome Evaluation (2016-2026) (US $MN)
14 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cancer Reporting to Meet State and Federal Regulations (2016-2026) (US $MN)
15 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Research & Clinical Studies (2016-2026) (US $MN)
16 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals & Medical Practices (2016-2026) (US $MN)
17 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Government Organizations & Third-Party Administrators (2016-2026) (US $MN)
18 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2016-2026) (US $MN)
19 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Private Payers (2016-2026) (US $MN)
20 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Research Centers (2016-2026) (US $MN)
21 Global Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Other End Users (2016-2026) (US $MN)
22 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
23 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Type (2016-2026) (US $MN)
24 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Integrated Software (2016-2026) (US $MN)
25 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Standalone Software (2016-2026) (US $MN)
26 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Deployment Model (2016-2026) (US $MN)
27 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cloud-Based Models (2016-2026) (US $MN)
28 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By On-Premise Models (2016-2026) (US $MN)
29 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Database Type (2016-2026) (US $MN)
30 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Commercial Databases (2016-2026) (US $MN)
31 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Public Databases (2016-2026) (US $MN)
32 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Functionality (2016-2026) (US $MN)
33 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Patient Care Management (2016-2026) (US $MN)
34 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Outcome Evaluation (2016-2026) (US $MN)
35 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cancer Reporting to Meet State and Federal Regulations (2016-2026) (US $MN)
36 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Research & Clinical Studies (2016-2026) (US $MN)
37 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals & Medical Practices (2016-2026) (US $MN)
38 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Government Organizations & Third-Party Administrators (2016-2026) (US $MN)
39 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2016-2026) (US $MN)
40 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Private Payers (2016-2026) (US $MN)
41 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Research Centers (2016-2026) (US $MN)
42 North America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Other End Users (2016-2026) (US $MN)
43 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
44 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Type (2016-2026) (US $MN)
45 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Integrated Software (2016-2026) (US $MN)
46 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Standalone Software (2016-2026) (US $MN)
47 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Deployment Model (2016-2026) (US $MN)
48 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cloud-Based Models (2016-2026) (US $MN)
49 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By On-Premise Models (2016-2026) (US $MN)
50 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Database Type (2016-2026) (US $MN)
51 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Commercial Databases (2016-2026) (US $MN)
52 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Public Databases (2016-2026) (US $MN)
53 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Functionality (2016-2026) (US $MN)
54 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Patient Care Management (2016-2026) (US $MN)
55 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Outcome Evaluation (2016-2026) (US $MN)
56 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cancer Reporting to Meet State and Federal Regulations (2016-2026) (US $MN)
57 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Research & Clinical Studies (2016-2026) (US $MN)
58 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals & Medical Practices (2016-2026) (US $MN)
59 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Government Organizations & Third-Party Administrators (2016-2026) (US $MN)
60 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2016-2026) (US $MN)
61 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Private Payers (2016-2026) (US $MN)
62 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Research Centers (2016-2026) (US $MN)
63 Europe Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Other End Users (2016-2026) (US $MN)
64 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
65 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Type (2016-2026) (US $MN)
66 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Integrated Software (2016-2026) (US $MN)
67 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Standalone Software (2016-2026) (US $MN)
68 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Deployment Model (2016-2026) (US $MN)
69 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cloud-Based Models (2016-2026) (US $MN)
70 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By On-Premise Models (2016-2026) (US $MN)
71 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Database Type (2016-2026) (US $MN)
72 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Commercial Databases (2016-2026) (US $MN)
73 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Public Databases (2016-2026) (US $MN)
74 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Functionality (2016-2026) (US $MN)
75 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Patient Care Management (2016-2026) (US $MN)
76 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Outcome Evaluation (2016-2026) (US $MN)
77 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cancer Reporting to Meet State and Federal Regulations (2016-2026) (US $MN)
78 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Research & Clinical Studies (2016-2026) (US $MN)
79 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals & Medical Practices (2016-2026) (US $MN)
80 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Government Organizations & Third-Party Administrators (2016-2026) (US $MN)
81 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2016-2026) (US $MN)
82 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Private Payers (2016-2026) (US $MN)
83 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Research Centers (2016-2026) (US $MN)
84 Asia Pacific Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Other End Users (2016-2026) (US $MN)
85 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
86 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Type (2016-2026) (US $MN)
87 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Integrated Software (2016-2026) (US $MN)
88 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Standalone Software (2016-2026) (US $MN)
89 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Deployment Model (2016-2026) (US $MN)
90 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cloud-Based Models (2016-2026) (US $MN)
91 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By On-Premise Models (2016-2026) (US $MN)
92 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Database Type (2016-2026) (US $MN)
93 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Commercial Databases (2016-2026) (US $MN)
94 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Public Databases (2016-2026) (US $MN)
95 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Functionality (2016-2026) (US $MN)
96 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Patient Care Management (2016-2026) (US $MN)
97 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Outcome Evaluation (2016-2026) (US $MN)
98 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cancer Reporting to Meet State and Federal Regulations (2016-2026) (US $MN)
99 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Research & Clinical Studies (2016-2026) (US $MN)
100 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals & Medical Practices (2016-2026) (US $MN)
101 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Government Organizations & Third-Party Administrators (2016-2026) (US $MN)
102 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2016-2026) (US $MN)
103 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Private Payers (2016-2026) (US $MN)
104 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Research Centers (2016-2026) (US $MN)
105 South America Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Other End Users (2016-2026) (US $MN)
106 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
107 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Type (2016-2026) (US $MN)
108 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Integrated Software (2016-2026) (US $MN)
109 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Standalone Software (2016-2026) (US $MN)
110 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Deployment Model (2016-2026) (US $MN)
111 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cloud-Based Models (2016-2026) (US $MN)
112 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By On-Premise Models (2016-2026) (US $MN)
113 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Database Type (2016-2026) (US $MN)
114 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Commercial Databases (2016-2026) (US $MN)
115 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Public Databases (2016-2026) (US $MN)
116 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Functionality (2016-2026) (US $MN)
117 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Patient Care Management (2016-2026) (US $MN)
118 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Outcome Evaluation (2016-2026) (US $MN)
119 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Cancer Reporting to Meet State and Federal Regulations (2016-2026) (US $MN)
120 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Research & Clinical Studies (2016-2026) (US $MN)
121 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals & Medical Practices (2016-2026) (US $MN)
122 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Government Organizations & Third-Party Administrators (2016-2026) (US $MN)
123 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2016-2026) (US $MN)
124 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Private Payers (2016-2026) (US $MN)
125 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Research Centers (2016-2026) (US $MN)
126 Middle East & Africa Cancer Registry Software ﾂ鮓ｹﾔｭｴｴ Outlook, By Other End Users (2016-2026) (US $MN)

Companies Mentioned:

Onco, Inc.
Rocky Mountain Cancer Data Systems
Mckesson Corporation
Elekta AB (PUB)
C/Net Solutions
Electronic Registry Systems, Inc

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.